Intellectual Property Safe Harbor May Be Shrinking After Years Of Growth
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers developing products with uncertain patent protection status should use data provided during FDA inspections as a benchmark for their potential inclusion in the IP safe harbor, according to RenalTech International VP-Regulatory Affairs Diane Minear
You may also be interested in...
Wesley Jessen Wins PureVision Patent Suit; B&L Weighs Limited Options
Bausch & Lomb is prohibited from selling its PureVision extended-wear contact lenses in the U.S. following a Washington, D.C. federal appeals court ruling Feb. 12
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.